Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. By the time this newsletter sends, I’ll be on a plane headed towards vacation. See you next week!
The need-to-know this morning
Alkermes CEO Richard Pops is retiring this summer, ending a 35-year run at the top of the neuroscience company. Blair Jackson, Alkermes’ current chief operating officer, will assume the CEO role.
GSK acquires pulmonary hypertension drug
The deal for privately held 35Pharma is small, just under $1 billion in cash, but it adds an experimental treatment for pulmonary arterial hypertension to GSK’s research pipeline and bolsters its recent shift towards respiratory and immunology medicines.Continue to STAT+ to read the full story…